Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marylore Chenel

Showing results (31-40 of 57) with videos related to

Pageof 6
Sort By:
British Journal of Pharmacology|May 25, 2004
Simultaneous central nervous system distribution and pharmacokinetic-pharmacodynamic modelling of the electroencephalogram effect of norfloxacin administered at a convulsant dose in ratsMarylore Chenel, Sandrine Marchand, Antoine Dupuis, et al.
Investigational New Drugs|May 31, 2014
Pharmacokinetic/Pharmacodynamic modeling of abexinostat-induced thrombocytopenia across different patient populations: application for the determination of the maximum tolerated doses in both lymphoma and solid tumour patientsQuentin Chalret du Rieu, Sylvain Fouliard, Mélanie White-Koning, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 4, 2026
Best Practices in Physiologically Based Pharmacokinetic (PBPK) ModelingMarylore Chenel, Andre Dallmann, Ibrahim Ince, et al.
Pharmaceutical Research|March 9, 2021
Modeling Approach to Predict the Impact of Inflammation on the Pharmacokinetics of CYP2C19 and CYP3A4 SubstratesFlorian Simon, Elodie Gautier-Veyret, Aurélie Truffot, et al.
Fundamental & Clinical Pharmacology|August 7, 2020
Impact of interleukin-6 on drug transporters and permeability in the hCMEC/D3 blood-brain barrier modelFlorian Simon, Laetitia Guyot, Jessica Garcia, et al.
The AAPS Journal|March 29, 2018
Correction to: Model-Based Adaptive Optimal Design (MBAOD) Improves Combination Dose Finding Designs: an Example in OncologyPhilippe B Pierrillas, Sylvain Fouliard, Marylore Chenel, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 20, 2018
Tumor Growth Inhibition Modelling Based on Receptor Occupancy and Biomarker Activity of a New Bcl-2 Inhibitor in MicePhilippe B Pierrillas, Emilie Henin, Julien Ogier, et al.
The AAPS Journal|March 9, 2018
Model-Based Adaptive Optimal Design (MBAOD) Improves Combination Dose Finding Designs: an Example in OncologyPhilippe B Pierrillas, Sylvain Fouliard, Marylore Chenel, et al.
CPT: Pharmacometrics & Systems Pharmacology|October 28, 2025
The Evolving Role of In Vitro-In Vivo Correlation in Model-Informed Drug Development: A Multi-Stakeholder PerspectiveMarylore Chenel, Sylvain Fouliard, Emma Hansson, et al.
The AAPS Journal|December 22, 2019
Impact of Interleukin-6 on Drug-Metabolizing Enzymes and Transporters in Intestinal CellsFlorian Simon, Jessica Garcia, Laetitia Guyot, et al.
Pageof 6

Showing results (31-40 of 57) with videos related to

Sort By:
Pageof 6
British Journal of Pharmacology|May 25, 2004
Simultaneous central nervous system distribution and pharmacokinetic-pharmacodynamic modelling of the electroencephalogram effect of norfloxacin administered at a convulsant dose in ratsMarylore Chenel, Sandrine Marchand, Antoine Dupuis, et al.
Investigational New Drugs|May 31, 2014
Pharmacokinetic/Pharmacodynamic modeling of abexinostat-induced thrombocytopenia across different patient populations: application for the determination of the maximum tolerated doses in both lymphoma and solid tumour patientsQuentin Chalret du Rieu, Sylvain Fouliard, Mélanie White-Koning, et al.
CPT: Pharmacometrics & Systems Pharmacology|July 4, 2026
Best Practices in Physiologically Based Pharmacokinetic (PBPK) ModelingMarylore Chenel, Andre Dallmann, Ibrahim Ince, et al.
Pharmaceutical Research|March 9, 2021
Modeling Approach to Predict the Impact of Inflammation on the Pharmacokinetics of CYP2C19 and CYP3A4 SubstratesFlorian Simon, Elodie Gautier-Veyret, Aurélie Truffot, et al.
Fundamental & Clinical Pharmacology|August 7, 2020
Impact of interleukin-6 on drug transporters and permeability in the hCMEC/D3 blood-brain barrier modelFlorian Simon, Laetitia Guyot, Jessica Garcia, et al.
The AAPS Journal|March 29, 2018
Correction to: Model-Based Adaptive Optimal Design (MBAOD) Improves Combination Dose Finding Designs: an Example in OncologyPhilippe B Pierrillas, Sylvain Fouliard, Marylore Chenel, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 20, 2018
Tumor Growth Inhibition Modelling Based on Receptor Occupancy and Biomarker Activity of a New Bcl-2 Inhibitor in MicePhilippe B Pierrillas, Emilie Henin, Julien Ogier, et al.
The AAPS Journal|March 9, 2018
Model-Based Adaptive Optimal Design (MBAOD) Improves Combination Dose Finding Designs: an Example in OncologyPhilippe B Pierrillas, Sylvain Fouliard, Marylore Chenel, et al.
CPT: Pharmacometrics & Systems Pharmacology|October 28, 2025
The Evolving Role of In Vitro-In Vivo Correlation in Model-Informed Drug Development: A Multi-Stakeholder PerspectiveMarylore Chenel, Sylvain Fouliard, Emma Hansson, et al.
The AAPS Journal|December 22, 2019
Impact of Interleukin-6 on Drug-Metabolizing Enzymes and Transporters in Intestinal CellsFlorian Simon, Jessica Garcia, Laetitia Guyot, et al.
Pageof 6